Recruiting
Phase 2

A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia

Sponsor:

Janssen Research & Development, LLC

Code:

NCT05963074

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell

Small Lymphocytic Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Ibrutinib

Venetoclax

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information